SCHEMBL2834535

SCHEMBL2834535

CCOC(=O)c1ccc(-c2ccc(CC)cc2)c(-c2ccccn2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.45
TLR7 Q9NYK1 1/20 0.42
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
F2 P00734 1/20 0.41
F12 P00748 1/20 0.41
GABRA2 P47869 4/20 0.41
GABRB2 P47870 4/20 0.41
MAPT P10636 1/20 0.41
JMJD6 Q6NYC1 1/20 0.41
KDM4E B2RXH2 3/20 0.40
HSD17B10 Q99714 2/20 0.40
CASP1 P29466 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA2B P29275 1/20 0.40
ADORA1 P30542 1/20 0.40
ALDH1A1 P00352 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2829639 0.90 TLR7 (0.45) LMNATLR7NPC1RAB9AF2
SCHEMBL2833219 0.84 CYP1A2 (0.54) LMNACYP1A2NPC1RAB9AGABRA2
SCHEMBL2830731 0.84 CYP1A2 (0.54) LMNACYP1A2NPC1RAB9AGABRA2
SCHEMBL2832834 0.81 S1PR3 (0.51) CYP1A2HSD17B10ALDH1A1HPGD
SCHEMBL2833745 0.78 CYP1A2 (0.61) LMNACYP1A2MEN1NPC1RAB9A
SCHEMBL13292044 0.78 CYP1A2 (0.53) LMNACYP1A2NPC1RAB9AGABRA2
SCHEMBL2832078 0.77 CYP1A2 (0.50) LMNACYP1A2GABRA2GABRB2MAPT
SCHEMBL2829645 0.76 MAPT (0.51) CYP1A2MEN1KMT2AGABRA2GABRB2
SCHEMBL2834572 0.76 CYP1A2 (0.55) LMNACYP1A2NPC1RAB9AGABRA2
SCHEMBL2837678 0.76 CYP1A2 (0.55) LMNACYP1A2NPC1RAB9AGABRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728014-B2 Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist biological activity ALLERGAN, INC. 2010-06-01 US disclosed
EP-2066633-A1 HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY Allergan, Inc. (US) 2009-06-10 EP disclosed
EP-2064183-A2 HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY Allergan, Inc. (US) 2009-06-03 EP disclosed
WO-2008030843-A1 HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2008-03-13 WO disclosed
WO-2008030838-A2 HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2008-03-13 WO disclosed
US-20080064872-A1 HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. 2008-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064872-A1 HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY S1PR4, S1PR3, S1PR1 LMNA 3120/4885CYP1A2 1133/4885TLR7 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.